Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 339,443 |
Reported balance
After 2023-02-28 transaction · row 1
1 source rowRow 1 · 2023-02-28 · Tax withholding · Disposed 6,247 · Balance 339,443 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2023 Filed Mar 3, 2023 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,247 | $99.77 | $623,263.19 |
DisclosureSEC source: 0001415889-23-003897 · form4-03032023_120325.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,443 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 62,527 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003048 · form4-02222023_110254.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,527 Underlying: Common Shares · 62,527 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,842 on February 17, 2024, 20,842 on February 17, 2025, and 20,843 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003048 · form4-02222023_110254.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,690 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,086 | $122.41 | $867,397.26 |
DisclosureSEC source: 0001415889-22-002188 · form4-03022022_040351.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,835 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 72,342 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001732 · form4-02232022_050247.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,342 Underlying: Common Shares · 72,342 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,114 on February 18, 2023, 24,114 on February 18, 2024, and 24,114 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001732 · form4-02232022_050247.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,921 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 149,600 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001415889-21-005966 · form4-12152021_031259.xml · derivative · entry 3 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 149,600 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 149,600 | $135.05 | $20,203,704.40 |
DisclosureSEC source: 0001415889-21-005966 · form4-12152021_031259.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,398 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.295 inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 149,600 | $34.94 | $5,227,024.00 |
DisclosureSEC source: 0001415889-21-005966 · form4-12152021_031259.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,267 | $121.58 | $1,126,681.86 |
DisclosureSEC source: 0001415889-21-001199 · form4-03022021_040356.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,398 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 71,070 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000887 · form4-02232021_030259.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,070 Underlying: Common Shares · 71,070 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,690 on February 19, 2022, 23,690 on February 19, 2023, and 23,690 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000887 · form4-02232021_030259.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,665 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 52,300 | $0.00 Strike: $27.03 | $0.00 |
DisclosureSEC source: 0001179110-20-009446 · edgar.xml · derivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 52,300 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 52,300 | $111.86 | $5,850,278.00 |
DisclosureSEC source: 0001179110-20-009446 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,800 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 52,300 | $27.03 | $1,413,857.28 |
DisclosureSEC source: 0001179110-20-009446 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 50,100 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-20-005070 · edgar.xml · derivative · entry 4 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 50,100 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 18,701 | $96.28 | $1,800,595.86 |
DisclosureSEC source: 0001179110-20-005070 · edgar.xml · nonDerivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,800 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.14 to $96.52, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 31,399 | $95.63 | $3,002,730.33 |
DisclosureSEC source: 0001179110-20-005070 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,501 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.14 to $96.135, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 50,100 | $22.39 | $1,121,834.19 |
DisclosureSEC source: 0001179110-20-005070 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,704 | $79.19 | $689,269.76 |
DisclosureSEC source: 0001179110-20-002915 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,800 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 103,446 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002279 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,446 Underlying: Common shares · 103,446 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 34,482 on February 21, 2021, 34,482 on February 21, 2022, and 34,482 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 16,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002279 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,504 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 46,900 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-19-008035 · edgar.xml · derivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 46,900 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 46,900 | $85.00 | $3,986,500.00 |
DisclosureSEC source: 0001179110-19-008035 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,535 Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 46,900 | $26.19 | $1,228,212.51 |
DisclosureSEC source: 0001179110-19-008035 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,132 | $77.23 | $705,264.36 |
DisclosureSEC source: 0001179110-19-003112 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,535 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 101,519 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002638 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,519 Underlying: Common shares · 101,519 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 33,839 on February 22, 2020, 33,840 on February 22, 2021, and 33,840 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002638 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,667 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 64,900 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001179110-18-009933 · edgar.xml · derivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 64,900 shares Expires 2019-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 64,900 | $65.00 | $4,218,500.00 |
DisclosureSEC source: 0001179110-18-009933 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,300 Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 64,900 | $26.02 | $1,688,373.50 |
DisclosureSEC source: 0001179110-18-009933 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,958 | $60.55 | $481,856.90 |
DisclosureSEC source: 0001179110-18-003301 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,300 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 155,495 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002532 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,495 Underlying: Common shares · 155,495 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 51,832 on 02/16/2019, 51,831 on 02/16/2020, and 51,832 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 28,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002532 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,258 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,815 | $45.46 | $491,649.90 |
DisclosureSEC source: 0001179110-17-003677 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,982 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 93,400 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · derivative · entry 5 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 93,400 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 93,400 | $45.00 | $4,203,000.00 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · nonDerivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,797 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 93,400 | $26.70 | $2,493,527.82 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 98,714 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · derivative · entry 4 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,714 Underlying: Common shares · 98,714 shares Expires 2027-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,905 on 2/17/2018, 32,904 on 2/17/2019, and 32,905 on 2/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002952 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,797 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 22,000 | $0.00 Strike: $24.38 | $0.00 |
DisclosureSEC source: 0001179110-16-031866 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 22,000 shares Expires 2017-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 22,000 | $24.38 | $536,386.40 |
DisclosureSEC source: 0001179110-16-031866 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,980 | $39.52 | $394,409.60 |
DisclosureSEC source: 0001179110-16-020707 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,524 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 214,041 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019916 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,041 Underlying: Common shares · 214,041 shares Expires 2026-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 71,347 on 02/19/2017, 71,347 on 02/19/2018, and 71,347 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019916 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,504 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 12,312 | $47.61 | $586,174.32 |
DisclosureSEC source: 0001179110-15-004034 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,090 Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 165,292 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003367 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,292 Underlying: Common shares · 165,292 shares Expires 2025-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 55,098 on 2/20/16, 55,097 on 2/20/17, and 55,097 on 2/20/18. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003367 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,402 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 83,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-15-002007 · edgar.xml · derivative · entry 31 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 83,000 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,500 | $45.71 | $114,275.00 |
DisclosureSEC source: 0001179110-15-002007 · edgar.xml · nonDerivative · entry 30 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,653 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.